Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsVentura County Armodafinil Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentVentura County Health Care PlanPolicy N/A

    Armodafinil (Nuvigil) Prior Authorization

    Customize your policy alerts

    Sign up for all venturacountyhealthcareplan policy alerts

    Know when venturacountyhealthcareplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization for armodafinil (Nuvigil) used to promote wakefulness in members with narcolepsy, obstructive sleep apnea/hypopnea syndrome, or shift-work disorder. Providers must submit diagnostic confirmation and, when applicable, documentation of prior positive-airway-pressure treatment and ongoing symptoms.

    Policy Summary
    PayerVentura County Health Care Plan
    PolicyArmodafinil (Nuvigil) Prior Authorization
    Policy CodePolicy N/A
    Change TypeRevised
    Effective DateJul 21, 2020
    Last ReviewFeb 20, 2026
    Next Review DateN/A
    Key ActionSubmit a documented diagnosis with sleep-lab confirmation for narcolepsy or polysomnography confirmation for OSAHS.
    SourceLink
    POLICY UPDATE CHANGES

    The February 18, 2025 revision updated the armodafinil definition and precautions section.

    The February 18, 2025 revision added references addressing pregnancy outcomes and serious cutaneous reactions associated with armodafinil or modafinil.

    3Wakefulness-related indications addressed
    12 weeksCPAP/BiPAP trial required
    150–250 mgAdult daily dose for narcolepsy and OSA
    150 mg

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Adult daily dose for shift-work disorder
    SeriousReported severe skin reactions

    Armodafinil Coverage Criteria

    Initial Armodafinil Authorization

    Covered for initial armodafinil authorization when the member has a documented diagnosis meeting <strong>one</strong> of the following pathways:

    ONE of the following diagnosis pathways

    • ALL of the following

      • Documented diagnosis of narcolepsy.
      • Narcolepsy is confirmed by sleep lab evaluation.
    • ALL of the following

      • Documented diagnosis of obstructive sleep apnea/hypopnea syndrome (OSAHS).
      • OSAHS is confirmed by polysomnography (a study on sleep cycles and behavior).
      • ONE of the following OSAHS conditions

        • Member is currently using an oral/dental appliance.
        • Member has undergone uvulopalatopharyngoplasty (UPPP).
        • Member is greater than or equal to 65 years of age.>= 65 years
        • Adequate CPAP/BiPAP trial

          • Member has completed an adequate therapeutic trial of twelve weeks of continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BiPAP).>= 12 weeks
          • Member is compliant with and currently using CPAP/BiPAP treatment.
    • ALL of the following

      • Documented shift-work disorder.
      • Excessive sleepiness is associated with shift-work disorder.

    Key Qualification Thresholds

    CPAP/BiPAP pathway
    Required trialComplete an adequate therapeutic trial of CPAP/BiPAP for 12 weeks.
    Ongoing treatmentThe member must be compliant with and currently using CPAP/BiPAP treatment.
    Persistent symptomsThe member must continue to experience excessive sleepiness despite CPAP/BiPAP use.
    Age criterion for OSAHS
    Minimum age65 years or older.
    Applicable conditionThis is a qualifying circumstance for the obstructive sleep apnea/hypopnea syndrome (OSAHS) pathway.
    Diagnostic confirmation

    Authorization and Documentation Requirements

    Prior Authorization

    Pre-Authorization Diagnosis Criteria

    Before authorization, submit documentation showing a diagnosis of narcolepsy or obstructive sleep apnea/hypopnea syndrome (OSAHS), along with the applicable diagnostic confirmation and qualifying documentation.

    • Diagnosis must be documented in the member’s clinical record.
    • The diagnosis and supporting evidence must satisfy the confirmation and OSAHS qualification requirements below.
    Documentation Required

    Diagnostic Confirmation Required

    Narcolepsy must be confirmed by a sleep-lab evaluation. OSAHS must be confirmed by polysomnography, documenting the sleep-cycle and behavioral findings supporting the diagnosis.

    • Narcolepsy: sleep-lab evaluation required.
    • OSAHS: polysomnography required.

    Clinical Background

    Armodafinil (Nuvigil) is the R-enantiomer of modafinil and an orally administered wakefulness-promoting agent. Its exact mechanism of action is unknown, although it generally inhibits dopamine reuptake. The policy addresses its use to promote wakefulness in patients with narcolepsy, obstructive sleep apnea/hypopnea syndrome (OSAHS), and excessive sleepiness associated with shift-work disorder.

    Key Definitions

    Armodafinil
    DefinitionArmodafinil is the R-enantiomer of modafinil.
    Therapeutic propertyIt is a wakefulness-promoting agent for oral administration.
    MechanismThe exact mechanism of action is unknown; armodafinil is generally known to inhibit dopamine reuptake.
    Obstructive sleep apnea/hypopnea syndrome
    Full termOSAHS means obstructive sleep apnea/hypopnea syndrome.
    Required confirmationThe diagnosis must be confirmed by polysomnography, a study of sleep cycles and behavior.
    Policy pathway

    Initial Authorization Pathway

    Initial Therapy Authorization

    Initial authorization requires a documented qualifying diagnosis and the applicable diagnostic confirmation.

    Qualifying diagnosis

    • Narcolepsy: Documented narcolepsy confirmed by sleep-lab evaluation.
    • OSAHS

      • Diagnostic confirmation: Documented obstructive sleep apnea/hypopnea syndrome (OSAHS) confirmed by polysomnography.
      • Applicable qualifying condition

        • Oral or dental appliance:

    Step Therapy Requirement

    StepRequirementMember must
    1Complete an adequate 12-week CPAP/BiPAP therapeutic trial.Remain compliant with and currently use CPAP/BiPAP treatment, while experiencing excessive sleepiness despite its use.
    Policy Summary
    PayerVentura County Health Care Plan
    PolicyArmodafinil (Nuvigil) Prior Authorization
    Policy CodePolicy N/A
    Change TypeRevised
    Effective DateJul 21, 2020
    Last ReviewFeb 20, 2026
    Next Review DateN/A
    Key ActionSubmit a documented diagnosis with sleep-lab confirmation for narcolepsy or polysomnography confirmation for OSAHS.
    SourceLink
    On This Page
    Armodafinil Coverage CriteriaKey Qualification ThresholdsAuthorization and Documentation RequirementsClinical BackgroundKey DefinitionsInitial Authorization PathwayStep Therapy Requirement
  1. Member is experiencing excessive sleepiness despite CPAP/BiPAP use.
  2. OSAHS must be confirmed by polysomnography.
    Documentation Required

    OSAHS Qualifying Documentation

    For OSAHS, provide documentation of at least one qualifying circumstance in addition to the confirmed diagnosis. The qualifying circumstance may be an oral/dental appliance, prior UPPP, age 65 or older, or the completed CPAP/BiPAP pathway described below.

    • Member is currently using an oral/dental appliance.
    • Member has undergone uvulopalatopharyngoplasty (UPPP).
    • Member is greater than or equal to 65 years of age.
    • Member has completed an adequate 12-week therapeutic CPAP/BiPAP trial and meets the ongoing-use and symptom requirements.
    Step Therapy

    Required CPAP/BiPAP Trial

    When qualification is based on positive airway pressure, document an adequate therapeutic trial of at least 12 weeks and show that the member remains compliant with and currently uses CPAP/BiPAP while experiencing excessive sleepiness despite treatment.

    • Adequate therapeutic CPAP/BiPAP trial: 12 weeks.
    • Member is compliant with and currently using CPAP/BiPAP.
    • Member continues to experience excessive sleepiness despite CPAP/BiPAP use.
    Denial Risk

    Diagnosis or Diagnostic Confirmation Missing

    Authorization may be denied when the submitted records do not establish an eligible diagnosis or do not include the required diagnostic confirmation. For narcolepsy, a sleep-lab evaluation is required; for OSAHS, polysomnography is required.

    • No documented diagnosis of narcolepsy or OSAHS.
    • Narcolepsy not confirmed by sleep-lab evaluation.
    • OSAHS not confirmed by polysomnography.
    • Required diagnostic study or supporting documentation is missing.
    Denial Risk

    OSAHS Positive-Airway-Pressure Criteria Not Met

    For OSAHS, authorization may be denied when the positive-airway-pressure qualification pathway is incomplete, noncompliant, or unsuccessful. The record must establish all required elements of the 12-week trial and ongoing treatment response.

    • CPAP/BiPAP trial was less than 12 weeks or is not documented as adequate.
    • Member is not compliant with or is not currently using CPAP/BiPAP.
    • Excessive sleepiness despite CPAP/BiPAP use is not documented.
    • The CPAP/BiPAP pathway does not otherwise establish the required OSAHS qualification.
    For authorization, the confirmed diagnosis must also be accompanied by an applicable qualifying condition, such as oral/dental appliance use, prior UPPP, age 65 years or older, or a qualifying CPAP/BiPAP history.
    Member is currently using an oral/dental appliance.
  3. UPPP history: Member has undergone uvulopalatopharyngoplasty (UPPP).
  4. Age criterion: Member is 65 years of age or older.>= 65 years
  5. CPAP/BiPAP pathway

    • Current compliant use: Member is compliant with and currently using CPAP/BiPAP treatment.
    • Persistent excessive sleepiness: Member is experiencing excessive sleepiness despite CPAP/BiPAP use.